Novonesis A/S Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Decisions with the Full Value Chain Report
This Novonesis A/S Value Chain Analysis gives you a clear, structured view of how the company creates value across support and primary activities. What you see on this page is a real preview of the actual deliverable, so you can review the content before buying. Purchase the full version to access the complete ready-to-use analysis.
Support Activities
Firm Infrastructure
Novonesis A/S was formed in 2024 from Novozymes and Chr. Hansen, so firm infrastructure now has to run one global board, one control system, and one capital plan. In 2025, that setup supports an integrated biosolutions platform serving food, health, and agriculture end markets, where regulatory checks and IP governance are central. The merger also makes reporting, risk control, and cash allocation a core value-chain task, not just back-office work.
Human Resource Management
In fiscal 2025, Novonesis A/S had about 10,000 employees, and that talent base is core to Human Resource Management. The mix of scientists, fermentation specialists, application engineers, and commercial teams helps turn biology into customer results, while training and retention support faster scale-up and steadier delivery across food, household care, agriculture, and nutrition. A workforce this large also matters financially, because even small gains in skill and retention can protect a DKK 11.9 billion revenue base and reduce costly process errors.
Technology Development
In FY2025, Novonesis A/S kept technology development at the center of its value chain, using microbial strains, enzyme engineering, formulation, and application testing to lift performance and cut environmental impact. This work supports products that fit more than 30 industries, from food to bioenergy. The result is faster product renewal and stronger margins from differentiated solutions.
Procurement
Novonesis A/S sources fermentation inputs, lab materials, packaging, utilities, and specialized equipment from a wide supplier base, so procurement is a direct lever on cost and supply security. Because biological production depends on tight specs and steady input quality, even small sourcing failures can hurt yield and batch consistency. In 2025, the merged Novonesis A/S had to manage a larger, more complex supply chain, making supplier control and dual sourcing especially important.
Novonesis FY2025: One System Supporting DKK 11.9B Revenue
In FY2025, Novonesis A/S support activities centered on a DKK 11.9 billion revenue base, about 10,000 employees, and one post-merger control setup. Corporate infrastructure, HR, R&D, and procurement now work as one system to protect quality, speed scale-up, and manage bio-input supply risk.
| FY2025 | Key support data |
|---|---|
| Revenue | DKK 11.9 billion |
| Employees | About 10,000 |
| Focus | R&D, HR, procurement, governance |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Novonesis A/S inbound logistics centers on receiving feedstocks, nutrients, cultures, consumables, and packaging materials for biological production. Tight incoming checks and lot-level traceability cut contamination risk and help keep batch performance steady, which matters in enzyme and microbial output. In FY2025, this gatekeeping supports a business that reported DKK 30.7 billion in revenue and depends on stable supply quality to protect margins.
Operations
Novonesis A/S operations turn biological know-how into commercial products through strain development, fermentation, downstream processing, and formulation, and that scale matters because the business reported DKK 29.5 billion in revenue in 2025. Yield, purity, and batch repeatability are the main cost and quality levers, since even small swings can affect customer output in food, bioenergy, and health applications. Strong process control also supports margin stability, with 2025 adjusted EBITDA margin at about 35%.
Outbound Logistics
Novonesis A/S outbound logistics moves enzymes and microorganisms from global production sites to industrial customers and distribution partners, where timing matters because active ingredients can lose performance if handled poorly. In fiscal 2025, Novonesis A/S operated at scale across a worldwide customer base, so stock planning and route control are key to keeping uptime high. Cold-chain discipline, lot traceability, and on-time delivery help protect product activity and support repeat orders.
Marketing and Sales
Novonesis A/S markets through a technical, B2B sales model, not mass advertising. It uses application trials, joint development, and account management to show cost-in-use, sustainability, and performance gains before a wider rollout.
This fits a business built on long customer cycles and repeated use in food, household care, and agriculture, where proof beats brand reach. The sales team acts more like an application partner than a classic sales force.
Service
Novonesis A/S service goes beyond delivery, with troubleshooting, reformulation help, and application tuning that keep enzymes and biosolutions working on customer lines. This post-sale support helps clients fit local rules, machine limits, and product specs, which lowers failure risk and speeds adoption. Strong service also supports repeat orders and longer customer ties, since technical fit often matters more than price in specialty ingredients.
Novonesis: Fermentation-Led Growth with 35% EBITDA Margin
Novonesis A/S primary activities turn fermentation and downstream processing into enzymes, cultures, and biosolutions for food, bioenergy, and health uses. FY2025 revenue was DKK 29.5 billion, and adjusted EBITDA margin was about 35%.
Its sales model is technical and account-led, using trials, joint development, and application support to prove cost-in-use and performance. This helps protect repeat demand and pricing power.
Service closes the loop with troubleshooting and reformulation help, so customer lines stay stable and product fit stays high.
| FY2025 | Value |
|---|---|
| Revenue | DKK 29.5bn |
| Adj. EBITDA margin | 35% |
Full Version Awaits
Novonesis A/S Reference Sources
This preview is taken directly from the actual Novonesis A/S Value Chain Analysis document you'll receive after purchase. There are no placeholders or sample-only sections – just the same professional report in full form. Once you buy, the complete version is unlocked for immediate use.
Frequently Asked Questions
It emphasizes science-led product development and application support. Novonesis A/S creates value by linking enzymes and microorganisms to 4 end-markets: food and beverage, household care, agriculture, and animal nutrition. Its model rests on 2 core solution types, with technical validation and regulatory discipline doing much of the heavy lifting.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.